IP Library Granted Patent US 9,802,923
Granted Patent B2
US 9,802,923 · App. 14/652,807 · Granted Oct 31, 2017

Process for the preparation of pazopanib or salts thereof

Inventors: Rajesh Kumar (Unnao, IN); Prabhat Giri (New Delhi, IN); Dhiren C. Barman (Gurgaon, IN); Asok Nath (Gurgaon, IN); Mohan Prasad (Haryana, IN)
Assignee: Sun Pharmaceutical Industries Limited
C07D403/12
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,802,923
App. No.
14/652,807
Granted
Oct 31, 2017
Kind
B2
Abstract

The present invention provides a process for the preparation of pazopanib of Formula Ia or salts, and intermediates thereof.

Claims (12)

1. A process for the preparation of pazopanib of Formula Ia or salts thereof

comprising:

i) treating 2,3-dimethyl-6-nitro-2H-indazole with Raney nickel to obtain a compound of Formula II;

ii) treating the compound of Formula II at a temperature of 25° C. to 30° C. with 2,4-dichloropyrimidine to obtain a compound of Formula III

 wherein steps i) and ii) are carried out in a single solvent comprising methanol circumventing heating and cooling procedures, and without isolating the compound of Formula II from the reaction mixture;

iii) converting the compound of Formula III to pazopanib of Formula Ia or salts thereof; and

iv) isolating pazopanib of Formula Ia or salts thereof.

2. The process according to claim 1 , wherein the treatment of the compound of Formula II with 2,4-dichloropyrimidine is carried out in the presence of a base.

3. The process according to claim 2 , wherein the base is selected from the group consisting of an organic base and an inorganic base.

4. The process according to claim 3 , wherein the organic base is selected from the group consisting of N,N-diisopropylethylamine, triethylamine, tri-isopropylamine, N,N-2-trimethyl-2-propanamine, N-methylmorpholine, 4-dimethylaminopyridine, 2,6-di-tert-butyl-4-dimethylaminopyridine, 1,4-diazabicyclo[2.2.2]octane, and 1,8-diazabicyclo[5.4.0]undec-7-ene, or mixtures thereof.

5. The process according to claim 3 , wherein the inorganic base is selected from the group consisting of sodium carbonate, and potassium carbonate, sodium hydride, sodium bicarbonate, and potassium bicarbonate, or mixtures thereof.

6. The process according to claim 5 , wherein the base is sodium bicarbonate.

Assignments (2)
MERGER Recorded Jan 13, 2016
From: RANBAXY LABORATORIES LIMTED
To: SUN PHARMACEUTICAL INDUSTRIES LIMITED
Reel/Frame 037513/0475 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 23, 2015
From: KUMAR, RAJESH; GIRI, PRABHAT; BARMAN, DHIREN C.; NATH, ASOK; PRASAD, MOHAN
To: RANBAXY LABORATORIES LIMITED
Reel/Frame 035889/0018 →
Priority Claims (1)
IN 3897/DEL/2012 · Dec 17, 2012 · national
Continuity (1)
Related Publication 20150329526A1 · Nov 19, 2015